![Biomedicines | Free Full-Text | Considering the Experimental Use of Temozolomide in Glioblastoma Research | HTML Biomedicines | Free Full-Text | Considering the Experimental Use of Temozolomide in Glioblastoma Research | HTML](https://www.mdpi.com/biomedicines/biomedicines-08-00151/article_deploy/html/images/biomedicines-08-00151-g001-550.jpg)
Biomedicines | Free Full-Text | Considering the Experimental Use of Temozolomide in Glioblastoma Research | HTML
![Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trial - The Lancet Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trial - The Lancet](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/a7550501-8bc8-4c74-9995-11f0dbeca441/gr1.jpg)
Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trial - The Lancet
![Reverse swing‐M, phase 1 study of repurposing mebendazole in recurrent high‐grade glioma - Patil - 2020 - Cancer Medicine - Wiley Online Library Reverse swing‐M, phase 1 study of repurposing mebendazole in recurrent high‐grade glioma - Patil - 2020 - Cancer Medicine - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/a87c61bf-4589-4d90-b047-e2e73e947058/cam43094-fig-0001-m.jpg)
Reverse swing‐M, phase 1 study of repurposing mebendazole in recurrent high‐grade glioma - Patil - 2020 - Cancer Medicine - Wiley Online Library
![Temozolomide antagonizes oncolytic immunovirotherapy in glioblastoma | Journal for ImmunoTherapy of Cancer Temozolomide antagonizes oncolytic immunovirotherapy in glioblastoma | Journal for ImmunoTherapy of Cancer](https://jitc.bmj.com/content/jitc/8/1/e000345/F5.large.jpg)
Temozolomide antagonizes oncolytic immunovirotherapy in glioblastoma | Journal for ImmunoTherapy of Cancer
![POCKET.MD - Dosage Calculator for TEMODAR, Dosage calculator for TEMODAR ( temozolomide). For U.S. health care professionals only. This dosage c... POCKET.MD - Dosage Calculator for TEMODAR, Dosage calculator for TEMODAR ( temozolomide). For U.S. health care professionals only. This dosage c...](http://www.pocket.md/images/appImages/screenshots/13089320141.jpg)
POCKET.MD - Dosage Calculator for TEMODAR, Dosage calculator for TEMODAR ( temozolomide). For U.S. health care professionals only. This dosage c...
![PDF] Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. | Semantic Scholar PDF] Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/9acdac652d4239e88054a03951d3af97d93786b4/3-Figure1-1.png)
PDF] Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. | Semantic Scholar
![Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II study - Annals of Oncology Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II study - Annals of Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/asset/d08d77a2-74e8-4ec0-ab34-9e6720b0bf86/gr1.jpg)
Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II study - Annals of Oncology
![Phase I study of temozolomide plus paclitaxel in patients with advanced malignant melanoma and associated in vitro investigations | British Journal of Cancer Phase I study of temozolomide plus paclitaxel in patients with advanced malignant melanoma and associated in vitro investigations | British Journal of Cancer](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fsj.bjc.6602438/MediaObjects/41416_2005_Article_BF6602438_Fig1_HTML.gif)
Phase I study of temozolomide plus paclitaxel in patients with advanced malignant melanoma and associated in vitro investigations | British Journal of Cancer
![These highlights do not include all the information needed to use TEMOZOLOMIDE CAPSULES safely and effectively. See full prescribing information for Temozolomide Capsules. Temozolomide Capsules Initial U.S. Approval: 1999 These highlights do not include all the information needed to use TEMOZOLOMIDE CAPSULES safely and effectively. See full prescribing information for Temozolomide Capsules. Temozolomide Capsules Initial U.S. Approval: 1999](https://dailymed.nlm.nih.gov/dailymed/image.cfm?name=temozolomide-capsules-1.jpg&id=448200)
These highlights do not include all the information needed to use TEMOZOLOMIDE CAPSULES safely and effectively. See full prescribing information for Temozolomide Capsules. Temozolomide Capsules Initial U.S. Approval: 1999
![Phase 2 Trial of Hypofractionated High-Dose Intensity Modulated Radiation Therapy With Concurrent and Adjuvant Temozolomide for Newly Diagnosed Glioblastoma - International Journal of Radiation Oncology, Biology, Physics Phase 2 Trial of Hypofractionated High-Dose Intensity Modulated Radiation Therapy With Concurrent and Adjuvant Temozolomide for Newly Diagnosed Glioblastoma - International Journal of Radiation Oncology, Biology, Physics](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/34588b90-e413-4a0a-abe6-e46bfd15823e/gr1.jpg)